Four manufacturers of the allergic rhinitis drug fluticasone nasal spray have announced shipment restrictions for their respective versions of the product, citing reasons including the impact of the New Year’s Day earthquake in central Japan and the Middle East crisis.
Nitto Medic, headquartered in Toyama, an area affected by the temblor, announced its shipment curb on February 5. The company decided on the measure as “a significant delay in the manufacturing plan was caused by the impact of the Noto Peninsula earthquake, which compounded the already unstable API supplies resulting from the situations in Israel,” it explained in a letter to healthcare professionals posted on its website.
Kyorin Rimedio and Towa Pharmaceutical, which started restrictions on February 5 and February 6, respectively, both cited contract manufacturer issues. According to their website information, the products subject to the measures this time are being manufactured by Nitto Medic.
Meanwhile, Teva Takeda Pharma, which markets fluticasone nasal spray as authorized generics, announced its curb on February 7, attributing the measure to the impact of shipment restrictions placed by other companies.
